KBC Securities - Akzo Nobel N.V. (AKU1) Morning Note: AKZA NA

Report

KBC Securities

Wim Hoste

Morning Note: AKZA NA

Akzo Nobel: Akzo starts bidding war for Tikkurila with € 31.25 bid

18/01/2021 1 EN

Underlying

Akzo Nobel N.V.

Akzo Nobel N.V. is a holding company. Through its subsidiaries, Co. is engaged in the production and marketing of paints, coatings and specialty chemicals. Co. has three segments: Decorative Paints, which supplies products for the professional and do-it-yourself markets, including paints, lacquers and varnishes, as well as products for surface preparation; Performance Coatings, which is divided into the following businesses: Automotive and Aerospace Coatings, Industrial Coatings, Marine and Protective Coatings, and Powder Coatings; and Specialty Chemicals, which are used in products such as ice cream, soups, disinfectants, plastics, soaps, detergents, cosmetics, paper and asphalt.

See profile

NL0000009132 Frankfurt Stock Exchange Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Wim Hoste

Other Reports on these Companies

SmartInsider

Akzo Nobel N.V.: 2 directors

Two Directors at Akzo Nobel N.V. bought 6,913 shares at between 55.036EUR and 55.200EUR. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rul...

Free Trial

April 25, 2025 April 25, 2025 1 EN

ING Financial Markets

Benelux Morning Notes

Ahold Delhaize: Release of 1Q24 company-compiled consensus. AkzoNobel: Decent 1Q24 with 4% beat, FY guidance reiterated. Allfunds Group plc: On the verge. Barco: Weak 1Q24, more conservative wording on guidance. DWS: 1Q24 preview. Flow Traders: No respite in March. IMCD: Last hurdle before growth. Randstad: 1Q24 slight miss vs consensus, 2Q24 outlook below due to weak gross margin. TKH Group: Preview – a weak 1Q expected Vår Energi: Nice start to the year

April 23, 2024 April 23, 2024 1 EN

ING Financial Markets

Benelux Morning Notes

AkzoNobel: 4Q23 narrowly misses, 2024 outlook, mid-term ambitions broadly in-line. Melexis: 4Q23 results; some weakness visible. UCB: Evenity going from one record to another. Universal Music Group: Supportive Spotify 4Q23 results

February 7, 2024 February 7, 2024 1 EN

Zealand Pharma Positive phase 1a data for Kv1.3 channel blocker

Zealand Pharma reported positive phase 1a topline results for the Kv1.3 channel blocker ZP9830. Single ascending doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings, and PK/PD profile was in-line with predictions. We view these data as de-risking for the program and look forward to the MAD data expected in 2H26, which should provide insight into extended exposure and additional proof of mechanism. Given the selective expression of Kv1.3 on effector memory T cells, we believe Kv1.3 blockers have pipeline-in-a-product potential in the at...

12h / 46m 12h / 46m 1 EN

Guy Sips ... (+6)

Guy Sips
Lynn Hautekeete
Mathijs Geerts Danau
Thibault Leneeuw
Thomas Couvreur
Wim Hoste

Morning Notes : AED BB, ASRNL NA, BAR BB, COFB BB, UMI BB, IMCD NA, ZEAL DC

: AED BB, ASRNL NA, BAR BB, COFB BB, UMI BB, IMCD NA, ZEAL DC

12h / 53m 12h / 53m 1 EN

Guy Sips

Guy Sips

Dynamic Top Pick List update Removing Aedifica

We remove Aedifica from our Dynamic Top Pick list after we updated our model after the FY25 reporting. Since we upgraded Aedifica early November from Hold to Buy, it outperformed the EPRA developed index by 15,1%. We expect the momentum to continue on a positive outcome from the initial exchange period and a potential MSCI inclusion. However we see limited upside to our € 80,0 fair value so we cut our recommendation from BUY to ACCUMULATE.

13h / 7m 13h / 7m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Note: AKZA NA

We are a financial services provider for several types of professional clients, each with distinct needs.

Akzo Nobel N.V.: 2 directors

Benelux Morning Notes

Benelux Morning Notes

Zealand Pharma Positive phase 1a data for Kv1.3 channel blocker

Morning Notes : AED BB, ASRNL NA, BAR BB, COFB BB, UMI BB, IMCD NA, ZEAL DC

Dynamic Top Pick List update Removing Aedifica

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe